Table 2.
Relative abundance of top 10 most abundant bacteria at genus level.
| All participants(N=171) | Group cured (N=61) a | Group intermediate(N=36) b | Group failed (N=33) c | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus | Healthy | BV patients | P valued | Pretreatment | Posttreatment | P valued | Pretreatment | Posttreatment | P valued | Pretreatment | Posttreatment | P valued |
| Relative abundance (%) of each genus, mean (95%CI) | ||||||||||||
| Lactobacillus | 78.95 (68.00-89.89) | 7.66 (5.16-10.15) | <.0001 | 10.06 (5.96-14.16) | 67.33 (57.78-77.09) | .0048 | 4.96 (1.53-8.38) | 11.46 (4.29-18.64) | .231 | 6.23 (0.92-11.54) | 23.23 (12.06-34.39) | .0761 |
| Gardnerella | 7.12 (1.70-12.54) | 35.61 (31.73-39.50) | <.0001 | 37.21 (31.93-42.50) | 22.32 (14.33-30.30) | <.0001 | 34.08 (26.07-42.09) | 25.74 (15.97-35.51) | .0946 | 34.38 (25.73-43.03) | 36.01 (26.72-45.30) | .980 |
| Prevotella | 0.98 (0.10-1.85) | 11.66 (9.64-13.68) | <.0001 | 10.73 (7.97-13.48) | 0.33 (0.10-0.56) | <.0001 | 14.07 (9.61-18.52) | 2.69 (0.78-4.60) | <.0001 | 10.74 (6.69-14.78) | 9.09 (4.99-13.19) | .1482 |
| Atopobium | 1.25 (-0.23-2.73) | 10.69 (8.08-13.31) | <.0001 | 8.27 (6.24-10.29) | 1.95 (0.29-3.61) | <.0001 | 12.35 (5.85-18.85) | 7.02 (1.33-12.71) | .0103 | 13.29 (6.54-20.04) | 12.07 (5.70-18.45) | .0657 |
| Megasphaera | 0.12 (-0.06-0.30) | 7.56 (6.04-9.08) | <.0001 | 9.08 (6.74-11.42) | 0.10 (0.045-0.16) | <.0001 | 5.74 (2.95-8.53) | 0.61 (-0.05-1.27) | .0005 | 6.78 (3.81-9.76) | 6.85 (3.56-10.15) | .7341 |
| Aerococcus | 0.60 (-0.40-1.59) | 3.77 (2.35-5.18) | <.0001 | 3.63 (2.02-5.24) | 0.93 (0.36-1.50) | <.0001 | 3.14 (0.81-5.48) | 3.38 (1.16-5.60) | .6507 | 4.70 (0.52-8.89) | 4.76 (0.60-8.91) | .7609 |
| Saccharofermentans | 0.12 (-0.096-0.33) | 3.26 (2.27-4.25) | <.0001 | 4.09 (2.40-5.79) | 0.04 (0.017-0.060) | <.0001 | 2.06 (0.58-3.54) | 0.15 (0.02-0.29) | .0013 | 3.06 (1.23-4.90) | 2.95 (0.91-4.99) | .8656 |
| Dialister | 0.30 (-1.96-2.55) | 2.95 (2.52-3.39) | <.0001 | 3.33 (-6.40-13.05) | 0.09 (-0.50-0.67) | <.0001 | 2.90 (-7.85-13.66) | 0.81 (-7.53-9.14) | <.0001 | 2.93 (1.23-4.62) | 2.82 (1.20-4.44) | .5207 |
| Streptococcus | 0.31 (0.045-0.57) | 0.95 (0.23-1.68) | <.0001 | 0.20 (0.019-0.39) | 1.13 (0.15-2.11) | .1953 | 2.28 (0.098-4.47) | 13.60 (4.64-22.56) | .0123 | 0.86 (-0.71-2.43) | 1.14 (-0.75-3.04) | .5391 |
| Enterococcus | 0.02 (0.004-0.05) | 0.82 (-0.10-1.74) | .290 | 0.12 (0.030-0.320 | 0.00 (0.00-0.002) | .0143 | 0.08 (0.0015-0.16) | 0.00 (0.00-0.01) | .009 | 1.99 (-1.46-5.44) | 1.15 (-0.97-3.28) | .7718 |
BV, bacterial vaginosis.
a “Group Cured” was defined as patients whose Nugent score were lowered to 0-3 after metronidazole treatment. b “Group Intermediate” was defined as patients whose Nugent score were changed to 4-6 after metronidazole treatment. c “Group Failed” was defined as patients whose Nugent score remained at 7-10 after metronidazole treatment. d Wilcoxon test was used for comparison between these two groups.